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Objectives. This study was designed to characterize physician
practices in the management of congestive heart failure (CHF)
and to determine whether these practices vary by specialty and
how they relate to guideline recommendations.
Background. Congestive heart failure is responsible for consid-
erable mortality, morbidity and health care resource utilization.
Although there have been important advances in the diagnostic
evaluation and treatment of CHF, little information is available
on physician practices in this area.
Methods. We surveyed physicians concerning their manage-
ment of patients with CHF. The results were analyzed in multi-
variate models to determine the relation of diagnostic and treat-
ment approaches to physician specialty, time since training, board
certification and volume of patients with CHF. Surveys were sent
to a sample of 2,250 family and general practitioners (FP/GPs),
internists and cardiologists. Responses were examined in relation
to guidelines issued by the Agency for Health Care Policy and
Research that had been released 9 months previously.
Results. Significant differences were found between physician
groups with regard to each of the major guideline recommenda-
tions. For example, routine evaluation of left ventricular function,
a point of emphasis in the guideline, is performed by 87% of
cardiologists, but by only 77% of internists and 63% of FP/GPs
(p < 0.001 between groups). Angiotensin-converting enzyme in-
hibitors were used by cardiologists, internists and FP/GPs in 80%,
71% and 60% of patients with mild to moderate CHF, respectively
(p < 0.001 between groups). Larger differences were reported in
the prescribed dosages of these drugs and their use in patients
with renal dysfunction.
Conclusions. Cardiologists report practices more in conformity
with published guidelines for CHF than do internists and FP/GPs.
Because of the large numbers of patients with CHF and their
substantial mortality, morbidity and cost of care, these differences
may have a major impact on outcomes and health care costs.
(J Am Coll Cardiol 1997;30:518–26)
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Congestive heart failure (CHF) is a major cause of morbidity
and mortality, affecting an estimated 4.7 million individuals,
with 470,000 new cases reported each year, and resulting in
875,000 hospital admissions in 1993 (1,2). It has been esti-
mated that the annual cost of managing patients with CHF
exceeds $10 billion (3,4). Although mortality rates from most
cardiovascular diseases have been falling (1,5), this has not
been the case for CHF (1,6). These trends continue despite
important advances in therapy, particularly with regard to the
ability of angiotensin-converting enzyme (ACE) inhibitors to
prolong survival and prevent hospitalization (7–10). However,
despite extensive publicity concerning these results and the
publication of practice guidelines by the Agency for Health
Care Policy and Research (AHCPR) in 1994 (3), it is uncertain
to what extent these advances have been implemented into
clinical practice. Indeed, the first area for future research
recommended by the AHCPR panel was that pertaining to the
question, “What are the current practice patterns for patients
with heart failure?” (3).
Previous studies have reported differences in clinical prac-
tices between generalists and specialists with regard to treating
several common conditions (11–15), including unstable angina
pectoris and myocardial infarction (16–19). Although most
patients with CHF are managed by generalists rather than
cardiologists (20), CHF is a complex problem, with a high rate
of treatment failures and rehospitalizations (21), and therefore
may be more optimally managed with the guidance of special-
ists or subspecialists. Therefore, the present study was under-
taken to survey the practices of family and general practitio-
ners (FP/GPs) internists and cardiologists with regard to the
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diagnosis, assessment and treatment of patients with CHF and
to compare these responses to the guidelines of the AHCPR,
which were published 9 months earlier.
Methods
Study group and sample size. To compare the self-
reported practices of these three groups of physicians, it was
estimated that responses from 250 physicians in each group
were required to achieve an 80% power (beta error 0.20) to
detect 10% absolute intergroup differences with an alpha error
of 0.05 (adjusted for multiple comparisons). Assuming a
minimal response rate of 40% and an undeliverable rate of
20%, surveys were mailed to 750 practitioners from each
group. This sample was randomly selected from the American
Medical Association’s Physician Masterfile. To maximize the
comparability of the three groups, they were stratified for
geographic distribution into four regions (East, Midwest,
South and West) and required to have a practice in a town or
city with at least 100,000 inhabitants. Physicians .65 years of
age were excluded, as were physicians within 5 years of
graduation.
Survey instrument. A questionnaire was developed specif-
ically for this study. The items analyzed for this study are
included in the Appendix. This survey was keyed to the major
points of the AHCPR guidelines (Table 1) so that the results
could be evaluated in reference to these evidence-based rec-
ommendations. Information was sought concerning 1) the
characteristics of the respondents and their practices, including
board certification, year of completion of training, number of
patients with CHF seen and practice setting; 2) the testing
procedures used in the diagnosis, assessment and follow-up of
patients with CHF; and 3) the approaches to initiating and
adjusting pharmacologic therapy. To provide a common refer-
ence from which to answer the questions related to treatment,
CHF was stated to be caused by left ventricular systolic
dysfunction (left ventricular ejection fraction #40%), and
patients were described as having “mild to moderate heart
failure,” defined as stable ambulatory outpatients with symp-
toms only on moderate exertion, or “severe, often unstable
heart failure,” defined as a patient with symptoms occurring
sometimes at rest. Response options were multiple choice or
check-boxes.
Conduct of survey. The timing of the survey distribution
(March 1995) was to start 9 months after the release of the
AHCPR guidelines. A reminder postcard was sent to all
physicians 10 days after the original mailing. After 21 days,
nonresponders were contacted by telephone to confirm their
address and encourage them to respond. After 28 days, a
second survey was sent by priority mail to nonresponding
physicians whose addresses could be confirmed. An indepen-
dent survey research firm (Freeman, Sullivan and Company)
coordinated the mailings and performed the telephone con-
tacts.
Data analysis. Univariate analyses were performed to
compare the responses of the physician groups. If the variable
was binary, the chi-square statistic was used. Because of the
multiple comparisons, a threshold of p 5 0.01 was set for
statistical significance. If the overall p value was ,0.01, then
pairwise comparisons were done. For continuous variables,
differences were examined using nonparametric statistics
(Kruskal-Wallis test); if the p value was ,0.01, then pairwise
comparisons were performed.
To determine whether medical specialty was an indepen-
dent predictor of the responses, other possible determinants,
such as year of training completion, board certification and
number of patients with CHF, were examined and controlled
for in multivariate analyses. For binary variables, multiple
logistic regression was used, and for continuous variables, a
general linear model was used. Analyses were performed with
SAS version 6 statistical software (SAS Institute). In multivar-
iate analyses, p 5 0.05 was set as the threshold for statistical
significance.
Results
Response rate to survey. Of 2,250 surveys mailed, 65 were
sent to physicians who were deceased or retired and 396 were
undeliverable at the addresses provided and could not be
traced by telephone. Of the remaining 1,789 valid names, 994
(55.6%) returned the questionnaire. This figure includes 342
(58.6%) of 584 FP/GPs, 325 (55.8%) of 582 internists and 327
(52.7%) of 621 cardiologists. Sixty responding physicians were
not included in the final analysis, based on predetermined
criteria of not seeing at least one patient with CHF per week
(n 5 42) or of not completing the entire survey (n 5 18),
leaving a total of 934 subjects. These were approximately
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AHCPR 5 Agency for Health Care Policy and Research
CHF 5 congestive heart failure
FP/GP 5 family and general practitioners
Table 1. Major Recommendations of the AHCPR Heart
Failure Guidelines
A. Diagnosis and evaluation
1. All patients with suspected CHF should have an assessment of left
ventricular function
B. Treatment
2. All patients with CHF due to left ventricular systolic dysfunction should
be treated with an ACE inhibitor unless contraindicated or not
tolerated
3. ACE inhibitors should be titrated to dosages used in clinical trials
4. Patients with asymptomatic left ventricular ejection fraction #35% to
40% should be treated with an ACE inhibitor
C. Follow-up
5. Patients with CHF should be followed up primarily by clinical
assessment, rather than by serial tests
ACE 5 angiotensin-converting enzyme; AHCPR 5 Agency for Health Care
Policy and Research; CHF 5 congestive heart failure.
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evenly distributed between the FP/GPs, internists and cardiol-
ogists (Table 2).
Characteristics of survey responders. Some of the salient
characteristics of the responding physicians are included in
Table 2. The median year of training completion and geo-
graphic distribution were similar in the three groups. The
proportion of physicians certified in their area of practice
increased with the degree of specialization. Although the great
majority of FP/GPs (72%) were primarily office-based, most
cardiologists were primarily hospital-based in their practice
and cardiologists saw more patients with heart failure on a
weekly basis. The nonresponders were similar to the respond-
ers with regard to specialty, gender and geographic distribu-
tion.
Diagnostic evaluation of patients with CHF. Several ques-
tions were used to evaluate the use of diagnostic tests in
patients with CHF (Table 3): FP/GPs (73%) and internists
(68%) reported using X-ray films to establish the diagnosis of
CHF more often than did cardiologists (47%), whereas cardi-
ologists indicated that they were more likely to use an echo-
cardiogram in making the initial diagnosis (48% vs. 15% for
FP/GPs and 22% for internists). Cardiologists reported assess-
ing left ventricular function in a higher proportion of their
CHF patients (92% vs. 69% by internists and 61% by FP/GPs).
Echocardiography was the primary modality for evaluating left
ventricular function. The reported utilization of several other
tests is also included in Table 3. Cardiologists were more likely
to perform stress tests and cardiac catheterization. If only
patients who were considered appropriate candidates for re-
vascularization and those who had angina are considered,
.90% of physicians in each group indicated that they would
order a stress test or coronary angiogram or refer the patient
to a specialist for further evaluation (data not shown). Of note,
the generalists rarely obtained cardiology consultations as part
of their initial evaluation of patients with CHF.
Treatment of patients with CHF. The responses to ques-
tions concerning CHF treatment are shown in Table 4 and
Figures 1 and 2. Even in mild CHF, only a minority of
physicians in each group indicated that they used a single drug
as their initial therapeutic approach. However, among these,
FP/GPs reported more use of diuretic agents; internists were
evenly split between a diuretic agent and ACE inhibitor; and
cardiologists were more likely to use an ACE inhibitor. Sixty-
two percent, 65% and 68% of the FP/GPs, internists and
cardiologists, respectively, indicated that combination therapy
was their initial approach (p 5 NS), but cardiologists claimed
a higher rate of prescribing three drugs (diuretic agents, ACE
inhibitors and digoxin) in combination. The percentage of
FP/GPs who reported using ACE inhibitors, either alone or in
combination with other medications, as part of their initial
regimen was significantly lower (60%) than that for internists
(74%) or cardiologists (85%) (Fig. 1). During maintenance
therapy, there were similar trends for the use of ACE inhibi-
tors, which were reported to be prescribed in 80% of patients
by cardiologists, 71% by internists and 60% by FP/GPs.
Cardiologists also indicated significantly higher utilization of
digoxin, nitrates, hydralazine and beta-blockers in their pa-
tients with mild to moderate CHF.
In patients with severe CHF, cardiologists indicated that
they were more likely to commence with a three-drug regimen
of a diuretic, ACE inhibitor and digoxin (71%) than FP/GPs
(51%) and internists (54%). An ACE inhibitor was included in
the initial regimen in 95% of the patients seen by cardiologists,
which was significantly more frequent than the use in patients
seen by internists and FP/GPs (82% and 77%), respectively.
Cardiologists also reported greater use of diuretic agents, ACE
inhibitors, digoxin, nitrates, hydralazine and beta-blockers.
Of note, this variation among physician groups with regard
to the use of ACE inhibitors occurred despite the fact that the
vast majority of FP/GPs, internists and cardiologists (91%,
92% and 98%, respectively) indicated awareness of clinical
trials demonstrating improved survival with ACE inhibitor
therapy in patients with CHF.
Differences in approaches to using ACE inhibitors. In
addition to using ACE inhibitors more frequently, cardiolo-
Table 2. Characteristics of Responders
FP/GP IM Card
No. of responses 342 325 327
Response rate 58.6% 55.8% 52.7%
Median year training completed 1978 1979 1980
Board certified 69% 79%* 90%†‡
Primary practice setting
Office 73% 54%* 23%†‡
Community hospital 15% 17% 45%†‡
University/government hospital 6% 21%* 27%†
.5 patients with CHF/week 31% 51%* 79%†‡
*p , 0.01 for internists (IM) versus family and general practitioners
(FP/GP). †p , 0.01 for cardiologists (Card) versus family and general practitio-
ners. ‡p , 0.01 for cardiologists versus internists. CHF 5 congestive heart
failure.
Table 3. Diagnostic Evaluation
FP/GP IM Card
Primary modality to diagnose CHF
X-ray film 73% 68% 47%†‡
Echocardiogram 15% 22% 48%†‡
Referral 7% 1% 0
Other 5% 9% 5%
LV function assessed 61% 69%* 92%†‡
Use of diagnostic tests
Echocardiogram 43% 59%* 83%†‡
Chest X-ray film 80% 88%* 82%
ECG 73% 83%* 91%†‡
Stress test 13% 21%* 35%†‡
Nuclear medicine test of EF 6% 10% 10%
Catheterization 5% 6% 20%†‡
Consultation 15% 7%* 0%†
*p , 0.01 for internists versus family and general practitioners. †p , 0.01 for
cardiologists versus family and general practitioners. ‡p , 0.01 for cardiologists
versus internists. ECG 5 electrocardiogram; EF 5 ejection fraction; LV 5 left
ventricular; other abbreviations as in Table 2.
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gists reported prescribing them in higher dosages. These
differences appear to stem from very different approaches to
titrating ACE inhibitors (Fig. 2). Although 74% of FP/GPs and
55% of internists said they use the lowest dose producing an
adequate symptom response, 78% of cardiologists advance to
a higher dose level unless the drug is not tolerated. Abnormal
renal function is one factor more likely to preclude the use of
ACE inhibitors by FP/GPs. Sixty-six percent of FP/GPs would
not use ACE inhibitors if the creatinine level is $2.5 mg/dl,
compared with 34% of cardiologists, with internists falling in
between (47%).
Cardiologists also reported using ACE inhibitors more
frequently in patients known to have asymptomatic left ven-
tricular dysfunction as evidenced by an ejection fraction ,40%
(75% vs. 55% vs. 62% for patients seen by cardiologists vs.
FP/GPs vs. internists, respectively; p , 0.001).
Approach to following patients with CHF. A plurality of
physicians from each group (48% of FP/GPs, 55% of internists
and 51% of cardiologists) stated that they used clinical assess-
ment as the primary mode of following patients being treated
for CHF. Of those using testing procedures, more FP/GPs and
internists than cardiologists reported using chest X-ray films
(31% and 27% vs. 13%, respectively), whereas more cardiol-
Figure 1. Percentage of physicians in each group who usually use an
ACE inhibitor (ACEI) as “first-line therapy,” either as a single drug or
in combination with other drugs, in patients with mild to moderate
(left) and severe (right) CHF. First-line therapy was defined as a single
initial medication or a combination of medications started together or
in a planned sequence. A significantly higher proportion of cardiolo-
gists (Card) used ACE inhibitors in this way for both grades of CHF,
and internists (IM) did so more frequently than FP/GPs for mild to
moderate CHF.
Figure 2. Physician approaches to administering ACE inhibitors
(ACEI). Solid bars indicate percent who use the lowest dose that
produces clinical improvement. Hatched bars represent percent who
titrate to a medium dose (defined as a total daily dose of 10 to 15 mg
of enalapril, 75 mg of captopril or the equivalent), if tolerated,
regardless of the response to lower doses. Open bars indicate percent
who routinely titrate to still higher doses, if tolerated. Cardiologists
(Card) are much more likely to use higher doses than are both FP/GPs
and internists (IM), and internists showed intermediate responses.
Table 4. Approach to Therapy of Patients With Congestive Heart Failure in Sinus Rhythm
Mild to Moderate CHF Severe CHF
FP/GP IM Card FP/GP IM Card
Initial therapy (% of physicians)
Diuretic alone 22% 17% 9%†‡ 7% 10% 4%‡
ACE inhibitor alone 11% 15% 20%† 4% 4% 4%
Digoxin alone 2% 1% 1% ,1% 2% ,1%
Diuretic and ACE inhibitor 33% 43%* 37% 20% 24% 19%
Diuretic and digoxin 13% 7% 3%† 7% 4% ,1%†
ACE inhibitor and digoxin 3% 3% 8% 2% 1% 1%
Diuretic, ACE inhibitor and digoxin 14% 12% 20%†‡ 51% 54% 71%†‡
Maintenance therapy (% of patients)
Diuretic 76% 78% 75% 88% 92% 96%†
ACE inhibitor 60% 71%* 80%†‡ 76% 84% 89%†
Digoxin 52% 53% 60%†‡ 72% 77% 83%†
Nitrates 19% 24%* 27%† 31% 40%* 40%†
Hydralazine 3% 5% 14%†‡ 4% 9% 12%†‡
Beta-blocker 4% 4% 9%†‡ 4% 4% 9%†‡
Calcium channel blocker 8% 8% 7% 9% 8% 7%
*p , 0.01 for internists versus family and general practitioners. †p , 0.01 for cardiologists versus family and general
practitioners. ‡p , 0.01 for cardiologists versus internists. Abbreviations as in Tables 1 and 2.
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ogists indicated that they used echocardiography (33% vs. 16%
and 15% for FP/GPs and internists, respectively).
Independent effects of time since training, board certifica-
tion and volume of patients with CHF. Because the physician
groups differed significantly in their proportion of physicians
indicating they were board certified in their stated field and the
number of patients with CHF they had seen, and cardiologists
also tended to have completed their training more recently,
multivariate analyses incorporating the variables of physician
group, years since completion of training, board certification
and number of patients with heart failure treated per week
were used to determine whether these additional factors could
explain the differences among the three categories of physi-
cians. For each survey item where differences were observed,
the physician group proved to be the most significant factor,
and the differences reflected the degree of specialization, with
FP/GPs differing most from cardiologists, and internists falling
between these two groups.
However, the year in which training was completed was an
independent predictor of each of the responses where physi-
cian specialty was significant. Physicians with more recent
training reported practice patterns more similar to specialists
than those with more distant training. Board certification also
proved to be a significant factor in the multivariate models.
Board certification was independently associated with more
frequent use of echocardiograms and greater use of ACE
inhibitors as initial therapy and during maintenance therapy.
Certified physicians also used higher doses of ACE inhibitors.
In contrast, after adjusting for the other factors, the number of
patients with CHF was not an independent predictor of any of
these practices.
Discussion
The primary findings of this study relate to the substantial
differences in reported practices between physicians with dif-
ferent training backgrounds. These differences were present
even though the survey was distributed after the dissemination
of guidelines for the management of CHF (3), and the majority
of physicians in each group expressed familiarity with the
results of the clinical trials on which these guidelines were
based. Furthermore, in the months before the survey, reports
containing the guideline recommendations appeared in the
published general medical data (22,23) as well as in numerous
closed-circulation publications. The principal recommenda-
tions of the AHCPR guidelines are summarized in Table 1,
and for each of these recommendations, the present study
demonstrates highly significant differences in self-reported
management practices for CHF among physicians with varying
degrees of specialization, with the cardiologists’ responses
conforming more closely than those of the internists and
FP/GPs. Of note, even within these groups, board certification
was also associated with greater conformity.
The demonstrated ability of ACE inhibitors to improve
prognosis in patients with CHF and asymptomatic left ventric-
ular dysfunction represents the major recent therapeutic ad-
vance in the management of CHF. As a result, several of the
guideline recommendations deal with the use of ACE inhibi-
tors. An encouraging finding is the substantial reported use of
ACE inhibitors by FP/GPs and internists in patients described
as having mild to moderate CHF, both as part of their initial
regimen (62% and 74%, respectively) and during maintenance
therapy (60% and 71%, respectively). These figures represent
a major practice shift since a survey conducted in 1984, when
only 9% of physicians considered a vasodilator as first-line
therapy (24). Even 5 years ago, only 32% of patients with the
diagnosis of CHF were found to be receiving ACE inhibitors
(25).
This increase in ACE inhibitor usage is confirmed by
marketing research as well (26). In a study of physicians
conducted just before the present survey, ACE inhibitors were
reported to be used in 46%, 58%, 80% and 87% of patients
with New York Heart Association functional class I, II, III and
IV symptoms, respectively. Angiotensin-converting enzyme
inhibitor usage by cardiologists was also higher than that for
generalists, especially in patients with milder symptoms (53%
vs. 44% for functional class I and 66% vs. 56% for class II).
However, in the present survey, more striking than the greater
reported usage of ACE inhibitors by cardiologists are the
differences in the manner in which these drugs are used. The
AHCPR guidelines recommend using the higher doses em-
ployed in the clinical trials demonstrating improved outcomes
with ACE inhibitor therapy, because the efficacy of lower doses
remains unestablished (27). Cardiologists indicate that they
more frequently titrate their patients to the dosages proven
efficacious in trials and are less reluctant to use ACE inhibitors
in patients with moderate renal dysfunction.
Other differences in reported medication usage warrant
comment. Cardiologists more frequently use digoxin, nitrates
and hydralazine, the other agents recommended by guidelines
for patients who remain symptomatic, than do generalists.
Importantly, however, few physicians in any of the groups state
that they use calcium channel blockers in patients with CHF,
which represents a distinct improvement from earlier observa-
tions in which these agents were frequently administered
(8,25). Differences between physician groups were also re-
ported for the use of diagnostic tests. The greater use of
echocardiograms by cardiologists in the initial evaluation of
patients with CHF is consistent with the guideline recommen-
dations for assessing left ventricular function. The greater use
of stress tests and cardiac catheterization by cardiologists also
is in keeping with the guideline recommendations to correct
reversible causes of CHF, including myocardial ischemia. The
relatively low usage of these last two tests by all three physician
groups may be indicative of the nature of CHF, because these
numbers are far higher when only patients who are suitable
candidates for revascularization are considered.
The higher use of these tests by cardiologists is consistent
with the previously reported greater use of diagnostic proce-
dures when heart failure is managed by cardiologists (28) and
the higher resource utilization by specialists in general
(15,17,29). From the present data, it is impossible to speculate
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as to whether the self-reported use of stress testing and
coronary angiography in 35% and 20% of their patients by
cardiologists is appropriate or excessive. It is also noteworthy
that only ;50% of physicians in all three groups followed their
patients primarily by clinical assessment, as recommended by
both the AHCPR and ACC/AHA guidelines. Among the
remainder, cardiologists were more likely to use echocardio-
grams and the FP/GPs and internists, chest X-ray films.
Study limitations. This study has several limitations. Al-
though the 55.6% response rate was comparable or higher than
that in many previous reports (16,24,28), it remains possible
that the results are not generalizable because of a selection
bias related to the level of knowledge and comfort with
treating CHF among physicians who chose to respond. The
comparable proportion of respondents in the three groups and
the absence of any systematic differences between the respond-
ers and nonresponders with regard to demographic variables,
however, makes it reasonable to compare them.
It is also uncertain whether the responses reflect the
physicians’ actual practices or are influenced by selective recall
or their desire to give the “correct” answer. Several studies
have highlighted the substantial discrepancies between physi-
cians’ self-reported practices and actual performance (30,31).
However, the similarity of the present study’s results to mar-
keting data derived from different methods does provide some
independent validation of the treatment results.
A third problem inherent in survey methodology is that the
physicians may have answered the questions from a different
frame of reference, because the characteristics of patients with
CHF usually treated by cardiologists, internists and FP/GPs
may differ. This potential problem was addressed by clearly
indicating in the questionnaire that CHF was caused by left
ventricular systolic dysfunction, and with regard to treatment,
by asking separate questions for stable outpatients defined as
having either “mild to moderate” or “severe” symptoms.
It is also important to note that these analyses were based
on group mean or median data and that many generalists may
have responded very similarly to some cardiologists, so it is
difficult to generalize about groups of physicians. In that
regard, the finding that year of training completion and board
certification are significant independent correlates of the re-
sponses indicates that there is considerable heterogeneity
within the physician groups.
Finally, it is crucial to emphasize that this study did not
compare patient outcomes or any measure of cost-effectiveness
between groups of generalists and specialists, but only their
self-described practices. This is a controversial area, fraught
with methodologic difficulties, and is beyond the scope of this
study.
Study implications. Several of the observed practice differ-
ences could potentially have important consequences. Without
routine measurements of left ventricular function, a substantial
number of patients with diastolic dysfunction might be treated
with agents, such as digoxin or vasodilators, with no demon-
strated benefit in this condition. The lower use of ACE
inhibitors by generalists in symptomatic patients with CHF and
in asymptomatic patients with left ventricular dysfunction, as
well as the lower dosages used by them when ACE inhibitors
are used, could have an adverse effect on morbidity and
mortality from this condition. Based on the results of clinical
trials of ACE inhibitors (8), the estimated numbers of patients
with CHF in the United States and the fact that the majority of
these patients are managed by generalists, the lower use of
ACE inhibitors among FP/GPs and internists might translate
into several thousand avoidable deaths and many more pre-
ventable hospital admissions.
These results raise several important questions. First, can
the practice patterns of the generalists be changed to make
them more consistent with guideline recommendations? The
rising proportion of patients receiving ACE inhibitors suggests
that progress is being made, but that it is slow and incomplete.
In that regard, it is noteworthy that only 41% of the FP/GPs
and 39% of the internists, compared with 59% of cardiologists,
indicated familiarity with the AHCPR guidelines, which had
been published 9 months earlier. A search for articles covering
the guideline material or review articles on the management of
CHF published in the 1993–1994 period uncovered only six
such reports in internal medicine, family and general practice
and geriatric journals published in the United States and listed
in Index Medicus (23,24,32–35). Nearly four times that number
were published in the four major cardiology journals published
in the United States. Thus, the necessary information may not
have been disseminated adequately to the groups least familiar
with it. This may explain the longer time lag between the
incorporation of new evidence-based recommendations into
the practices of generalists and specialists, and it also suggests
that smaller differences might be observed if this survey were
to be repeated after several years.
Even when appropriate information on new advances and
practice guidelines is provided, however, more direct interac-
tive communication may be required to change practice pat-
terns (36). Continuing medical education programs have also
had limited effectiveness in changing physician practices (37).
More innovative approaches should be considered (38).
The significant independent effect of time since completion
of training is instructive. It would appear that physicians who
are more recently out of training are more likely to be familiar
with and incorporate new advances into their practices.
Clearly, the challenge of remaining current in a wide spectrum
of evolving clinical practices is a difficult one, and it is not
surprising that specialists and subspecialists have an advantage
in their own fields.
This raises the question of whether cardiologists should be
more actively involved in managing of patients with CHF.
Current practice patterns and the trend toward more of a
“gatekeeper” role for generalists make it unlikely that all
patients with CHF will be followed by cardiologists, nor is
there evidence that doing so would improve their outcome.
However, it may not be unreasonable for many such patients to
be evaluated by a specialist and for a cardiologist to be
involved in the management of those with more severe CHF.
This latter group is responsible for a disproportionate number
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of deaths and resource utilization. In that regard, recent
studies have demonstrated that aggressive multidisciplinary
programs under the supervision of a specialist can prevent
rehospitalization of patients discharged with the diagnosis of
CHF and result in a net cost savings (39,40).
The present study is not unique in demonstrating poten-
tially important differences between specialists and generalists.
Previous studies have shown differences in treatment ap-
proaches of cardiologists and generalists in the management of
unstable angina pectoris and myocardial infarction (16–19).
These results, and those in other subspecialty areas (13–15),
raise the possibility that optimal management of some patients
with diseases for which practices are evolving rapidly and
which result in substantial mortality, morbidity and resource
utilization may include consultation or continuing involvement
by specialists. However, in the current climate of aggres-
sive cost reduction, improvements in outcomes and cost-
effectiveness will be required to support this conclusion.
We express our gratitude to Drs. David Baker, Stephen McPhee, Kevin
Grumbach, Andrew Bindman and Lee Goldman for their review of this
manuscript and their helpful comments and suggestions.
Appendix
Questions Used in Analysis
I. Diagnosis
1. Excluding the history and physical examination, what is the most
common primary modality you use to establish the diagnosis of heart
failure? (Select one.)
A. I do not use additional testing in the majority of my patients
B. Chest X-ray film
C. Echocardiogram
D. Nuclear medicine test of left ventricular function
E. Right heart catheterization
F. Cardiac catheterization including coronary angiography
G. I refer the patient for further evaluation
2. In new patients with symptoms of heart failure, in what percentage
of your patients do you order the following procedures as part of your
initial evaluation? Note, for this purpose the initial evaluation is
defined as procedures or tests ordered together or sequentially in
confirming the diagnosis. (Indicate percent. Total may exceed 100%.)
A. Referral to a consultant _______________________________%
B. Echocardiogram ______________________________________%
C. Chest X-ray film _____________________________________%
D. Stress test (exercise or pharmacologic) to detect ischemia __%
E. Electrocardiogram ____________________________________%
F. Nuclear medicine test of left ventricular function _________%
G. Cardiac catheterization and coronary angiography ________%
3. In what percentage of patients with newly diagnosed heart failure
do you assess left ventricular systolic function (by echocardiography,
nuclear medicine or cardiac catheterization)? __________________%
II. Treatment
Many classes of medications have been demonstrated to be useful
in heart failure, and there is no single standard treatment approach. In
the following section please indicate your current practice in the
treatment of heart failure in patients with left ventricular systolic
dysfunction (ejection fraction ,40%). (Questions 4 and 5 refer to
patients with mild to moderate heart failure, defined as a stable
ambulatory outpatient with symptoms only on moderate exertion.
Questions 6 and 7 refer to patients with severe, often unstable heart
failure, defined as a patient with symptoms occurring sometimes at
rest.)
4. In your patients with mild to moderate heart failure in normal
sinus rhythm, what is your usual choice of treatment for first-line
therapy? First-line therapy is defined as a single initial medication or
a combination of medications that may be started together or as a
planned sequence. (Select the single best answer.)
A. Diuretic agent
B. ACE inhibitor
C. Digoxin
D. Diuretic agent plus an ACE inhibitor
E. Diuretic agent plus digoxin
F. ACE inhibitor plus digoxin
G. Diuretic agent plus ACE inhibitor plus digoxin
5. In your patients with mild to moderate heart failure, what
percentage are taking each of the following drugs solely for the
indication of heart failure (i.e., not for angina or hypertension)?
(Please indicate the percentage of your patients on the following drugs.
Enter zero if you do not use a particular medication.)
A. Diuretic agents _______________________________________%
B. ACE inhibitors _______________________________________%
C. Digoxin _____________________________________________%
D. Nitrates _____________________________________________%
E. Hydralazine _________________________________________%
F. Beta-blockers ________________________________________%
G. Calcium channel blockers _____________________________%
6. In your patients with severe heart failure in normal sinus rhythm,
what is your usual choice of treatment for first-line therapy? First-line
therapy is defined as a single initial medication or a combination of
medications that may be started together or as a planned sequence.
(Select the single best answer.)
A. Diuretic agent
B. ACE inhibitor
C. Digoxin
D. Diuretic agent plus ACE inhibitor
E. Diuretic agent plus digoxin
F. ACE inhibitor plus digoxin
G. Diuretic agent plus ACE inhibitor plus digoxin
7. In your patients with severe heart failure, what percentage are
taking each of the following drugs solely for the indication of heart
failure (i.e., not for angina or hypertension)? (Please indicate the
percentage of your patients on the following drugs. Enter zero if you
don’t use a particular medication.)
A. Diuretic agents _______________________________________%
B. ACE inhibitors _______________________________________%
C. Digoxin _____________________________________________%
D. Nitrates _____________________________________________%
E. Hydralazine _________________________________________%
F. Beta-blockers ________________________________________%
G. Calcium channel blockers _____________________________%
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8. In all of your patients with heart failure who are taking an ACE
inhibitor for the treatment of left ventricular systolic dysfunction, what
percentage are taking low dose, medium dose and high dose therapy as
defined below? (Total should equal 100%.)
A. Low dose (captopril or Capoten ,50 mg/day total; enalapril or
Vasotec #5 mg/day total; lisinopril or Prinivil or Zestril
#5 mg/day total; quinapril or Accupril #10 mg/day total or the
equivalent) _________________________________________%
B. Medium dose (captopril 50 to 75 mg/day total; enalapril 6 to
15 mg/day total; lisinopril 6 to 15 mg/day total; quinapril 11 to
20 mg/day total or the equivalent) ______________________%
C. High dose (captopril .75 mg/day total; enalapril .15 mg/day
total; lisinopril .15 mg/day total; quinipril .20 mg/day total or
the equivalent) ______________________________________%
9. In a patient taking an ACE inhibitor for the treatment of heart
failure who does not develop side effects, what do you consider your
usual “target” dose to be? (Select the single best answer.)
A. The lowest dose producing an adequate symptomatic response?
B. A medium dose (as defined in Question 8), even if the patient
has responded to a lower dose?
C. A high dose (as defined in Question 8), even if the patient has
responded to a lower dose?
10. Is there a threshold of baseline decreased renal function that
would prevent you from using an ACE inhibitor initially? (Select the
single best answer.)
A. Creatinine $1.5 mg/dl
B. Creatinine $2.0 mg/dl
C. Creatinine $2.5 mg/dl
D. Creatinine $3.0 mg/dl
E. A higher threshold
11. What percentage of your patients with asymptomatic left
ventricular systolic dysfunction (ejection fraction ,40%) do you treat
with an ACE inhibitor? _____________________________________%
III. Follow-up
12. What is your primary modality in following clinically stable
patients with heart failure? (Select the single best answer.)
A. History and physical examination only
B. Chest X-ray film
C. Exercise tolerance test
D. Echocardiogram
E. Nuclear ejection fraction
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